News10/Ratings0
Latest news
10 items- PRKBL Merger Corp. IV Announces Completion of Acquisition of 180 Life Sciences Corp. and Trading Under the ticker ATNF Starting November 9, 2020NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- KBL Merger Corp. IV (NASDAQ: KBLM or the "Company"), a special purpose acquisition company (SPAC), today announced the successful completion of its acquisition of 180 Life Sciences Corp. ("180 Life Sciences"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain. In connection with the closing of the merger, KBLM issued 17,500,000 shares of common stock to the stockholders of 180 Life Sciences, of which 1,049,999 shares were deposited in an escrow account and subject to forfeiture for indemnification claims
- PRKBL Merger Corp. IV Announces Approval of Business Combination with 180 Life Sciences at the Special Meeting of Shareholders Held on November 5, 2020NEW YORK, Nov. 06, 2020 (GLOBE NEWSWIRE) -- KBL Merger Corp. IV (NASDAQ: KBLM or the "Company"), a special purpose acquisition company (SPAC) that previously announced an agreement to acquire 180 Life Sciences Corp. ("180 Life Sciences"), today announced that a special meeting (the “Meeting”) of the stockholders of KBL Merger Corp. IV (the “Company”) was held on November 5, 2020, where all proposals, including the proposal to approve the proposed business combination with 180 Life Sciences, were approved. In connection with the special meeting, stockholders of KBLM holding 816,461 public shares exercised their right to redeem such public shares into a pro rata portion of the Trust Accou
- PRKBL Merger Corp. IV Announces Change of Special Meeting of Shareholders Date to November 5, 2020NEW YORK, Oct. 23, 2020 (GLOBE NEWSWIRE) -- KBL Merger Corp. IV (NASDAQ: KBLM or the "Company"), a special purpose acquisition company (SPAC) that previously announced an agreement to acquire 180 Life Sciences Corp. ("180 Life Sciences"), today announced that the special meeting of its stockholders (the “Special Meeting”) originally scheduled for Monday, October 26, 2020, is being postponed to November 5, 2020. As a result of this change, the Special Meeting will now be held at 10:00 a.m., local time, on November 5, 2020, at the offices of KBL located at 30 Park Place, Suite 64B, New York, NY 10007. Also as a result of this change, the date and time by which stockholders seeking to ex
- PRInnovative Companies with Blockbuster Potential Catch SPAC AttentionNEW YORK, Oct. 23, 2020 (GLOBE NEWSWIRE) -- NetworkNewsAudio – 180 Life Sciences Corp., a clinical-stage biotechnology company that has entered into a definitive merger agreement with KBL Merger Corp. (NASDAQ: KBLM) (KBL Merger Corp. Rights NASDAQ: KBLMR) (KBL Merger Corp. Warrant NASDAQ: KBLMW), announces the availability of a broadcast titled “Banking on the Next Blockbuster Drug.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please click here. 180 Life Sciences Corp. was started by four world-renowned scientists and entrepreneurs who invested their own money to start the company. These scientists own the majority of the e
- PRIn Pursuit of the Elusive Drug -- the Billion-Dollar BlockbusterNEW YORK, Oct. 22, 2020 /PRNewswire/ -- Enormous amounts of money exchange hands in the big pharma space as companies merge and are acquired — all in search of the next blockbuster drug. While the discovery of a blockbuster drug, or a drug that generates more than $1 billion in sales per year, occurs rarely, the tremendous benefits of owning blockbuster therapeutics can mean tens of billions of dollars for a company during the patent-protected life of the drug. It makes sense, then, that pharmaceutical giants are in hot pursuit of what could be the next new drug — and the company that owns that drug. 180 Life Sciences Corp., a clinical-stage biotechnology company that has entered into a d
- PRUPDATE -- The Quest for Blockbuster Drugs ContinuesNEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsWire — 180 Life Sciences Corp., a clinical-stage biotechnology company that has entered into a definitive merger agreement with KBL Merger Corp. (NASDAQ: KBLM) (KBL Merger Corp. Rights NASDAQ: KBLMR) (KBL Merger Corp. Warrant NASDAQ: KBLMW), today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ brands in the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Banking on the Next Blockbuster Drug,” please visit here: Pharmaceutical companies invest enormous amounts of time and money on the res
- PRBlockbuster Year and Bright Horizons for SPACsNEW YORK, Oct. 13, 2020 /PRNewswire/ -- The year 2020 has already seen 127 SPAC IPOs, which have collectively raised over $48.5 billion in proceeds — more than the past ten years combined. A special purpose acquisition company (SPAC) is essentially a blank-check company formed to raise capital through an IPO with the sole intent of buying or merging with another operating company. SPACs have evolved to become an expedited and cost-effective way of doing an M&A deal and have been utilized by multiple Wall Street heavyweights. Going public via a SPAC enables a company to get a deal done in weeks instead of months, and the approach is proving to be an especially attractive vehicle for biotec
- PRLife-Saving Advancements, Treatments Delivered by Companies Invested in InnovationNEW YORK, Oct. 2, 2020 /PRNewswire/ -- Innovation and breakthroughs in the biotech industry are essential to identifying and providing life-saving treatments. Companies that invest substantial amounts of time, effort, and resources in key areas of research and innovation are critical in the advancement treatment options across the board. On the front lines of research and development in the area of inflammation, which typically occurs in the body as a natural response to threats such as infection or injury can cause severe damage and even death, is 180 Life Sciences Corp. (NASDAQ: KBLM) (180 Profile). The company is focused on groundbreaking studies in clinical programs designed to develo
- PRGroundbreaking Studies Offer Hope for Unmet Medical Needs in Inflammatory DiseaseNEW YORK, Oct. 01, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsWire -- 180 Life Sciences Corp. (NASDAQ: KBLM) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ brands in the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Solving One of the Largest Drivers of Disease: Inflammation,” please visit here: Inflammation typically occurs in the body as a natural response to threats such as infection or injury, but chronic inflammation can cause severe damage and even death. Inflammation is a well-known symptom of multiple infectious diseases. However, multi
- PRSolving One of the Largest Drivers of Disease: InflammationNEW YORK, Sept. 30, 2020 /PRNewswire/ -- Inflammation typically occurs in the body as a natural response to threats such as infection or injury, but chronic inflammation can cause severe damage and even death. Inflammation is a well-known symptom of multiple infectious diseases. However, multidiscipline research strongly suggests that inflammation is also closely linked with a broad range of noninfectious diseases. The critical aspects of the interplay between inflammation and disease may well be the key to development of a new generation of drugs to treat previously untreatable diseases, sparking a flurry of biotech research and development in the field. At the vanguard of this new drug